9989 — Shenzhen Hepalink Pharmaceutical Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$6.97bn
- HK$6.74bn
- CNY5.48bn
Annual cashflow statement for Shenzhen Hepalink Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | -1,304 | -1,533 | -1,597 | -1,224 | -1,442 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -6.63 | -757 | 398 | 2,194 | 1,713 |
| Capital Expenditures | -194 | -222 | -445 | -203 | -121 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 914 | 472 | 1,666 | -212 | -752 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 720 | 250 | 1,222 | -415 | -873 |
| Financing Cash Flow Items | -51.8 | -139 | 98.1 | -13.4 | -42.9 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -501 | 330 | -1,210 | -2,140 | -1,095 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 149 | -160 | 446 | -344 | -233 |